☆ 4.6 Article

Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study

JOURNAL OF CROHNS & COLITIS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis A Canadian IBD Research Consortium Multicenter National Cohort Study

Christopher Ma et al.

Summary: This Canadian multicenter cohort study evaluated the real-world effectiveness and safety of tofacitinib for the treatment of ulcerative colitis (UC). The study found that one-third of UC patients achieved clinical remission with few serious adverse events. However, half of the patients lost response with dose de-escalation, highlighting the importance of counseling patients with negative prognostic factors about the risks and benefits of continuing high doses of tofacitinib.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Miliary Tuberculosis in a Patient With Ulcerative Colitis Treated With Tofacitinib

Shruti Verma et al.

Summary: Immunosuppression with tumor necrosis factor-alpha inhibitors and tofacitinib increases the risk of reactivating latent tuberculosis and developing active tuberculosis. We present a case of miliary tuberculosis in a patient receiving treatment with tofacitinib for active ulcerative colitis. Despite a clinical response, the patient developed fever, night sweats, and myalgias. Further investigations revealed pulmonary miliary tuberculosis. Tofacitinib was discontinued and antitubercular therapy was initiated, leading to clinical and radiological improvement. This case report underscores the importance of screening for latent tuberculosis in patients receiving tofacitinib.

ACG CASE REPORTS JOURNAL (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment

William J. Sandborn et al.

Summary: Tofacitinib demonstrated consistent safety over up to 7.0 years, with data up to Month 36 supporting long-term efficacy in the treatment of ulcerative colitis patients.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Short-term effectiveness and safety of tofacitinib in ulcerative colitis-real world data from tertiary medical centers in Israel

Irit Avni-Biron et al.

Summary: Tofacitinib showed effectiveness and safety in treating moderate to severe ulcerative colitis in Israeli patients, achieving corticosteroid-free remission in about 20% of patients with extensive biologics experience. Despite some patients continuing to use tofacitinib at 26 weeks, it was well tolerated and safe. Earlier use of tofacitinib in the treatment algorithm may lead to improved outcomes.

DIGESTIVE AND LIVER DISEASE (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment

Tim Raine et al.

JOURNAL OF CROHNS & COLITIS (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Use of thiopurines in inflammatory bowel disease: an update

Arshdeep Singh et al.

Summary: Inflammatory bowel disease (IBD) is now a global disease, with treatment mainly involving biologics and thiopurines, although their use is limited in developing countries. Thiopurines are critical for IBD patients in these regions, but face restrictions in usage.

INTESTINAL RESEARCH (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

Michael Chiorean et al.

Summary: This study described the real-world treatment experience and corticosteroid utilization of patients with UC treated with tofacitinib. The results showed high adherence and low discontinuation of tofacitinib, as well as decreased use of oral corticosteroids regardless of prior biologic use.

BMC GASTROENTEROLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis

William J. Sandborn et al.

Summary: In patients with ulcerative colitis who did not respond to initial treatment with tofacitinib, extended induction therapy (16 weeks) with 10 mg twice daily led to more than half of the patients (52.2%) achieving clinical response. Most delayed responders who continued to receive tofacitinib therapy were in remission at Month 36.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and efficacy of long-term tofacitinib treatment in East Asian patients with ulcerative colitis in OCTAVE Open

Katsuyoshi Matsuoka et al.

Summary: This study presents safety and efficacy data of tofacitinib for the treatment of ulcerative colitis in East Asian patients. The results show that the safety and efficacy of tofacitinib are consistent with the global study population, although the occurrence rate of herpes zoster is slightly higher in East Asian patients.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry

Maria Chaparro et al.

Summary: The study findings indicate that tofacitinib is effective and safe in treating active ulcerative colitis. However, a significant proportion of patients discontinue the drug over time, mainly due to primary failure.

JOURNAL OF CROHNS & COLITIS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data

Jeffrey R. Curtis et al.

Summary: This study aimed to compare the overall incidence of safety events in UC patients in a real-life population cohort with the tofacitinib UC clinical trial program. Results showed that compared with the UC trial-like cohort, patients treated with tofacitinib had lower incidence rates for some safety events but higher rates for herpes zoster.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis

Stephen Hanauer et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

William J. Sandborn et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

ACG Clinical Guideline: Ulcerative Colitis in Adults

David T. Rubin et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Persistence With Immunomodulator Monotherapy Use And Incidence of Therapeutic Ineffectiveness Among Users of Immunomodulator Monotherapy in IBD

Laura E. Targownik et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)

添加到收藏夹

Article Gastroenterology & Hepatology

Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Marcus Harbord et al.

JOURNAL OF CROHNS & COLITIS (2017)

添加到收藏夹

Article Medicine, General & Internal

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Review Gastroenterology & Hepatology

Guidelines for the management of inflammatory bowel disease in adults

Craig Mowat et al.

GUT (2011)

添加到收藏夹

Review Gastroenterology & Hepatology

American Gastroenterological Association institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

GR Lichtenstein et al.

GASTROENTEROLOGY (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.